Is IFF a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for International Flavors & Fragrances Inc. (IFF) rests on The Food Ingredients sale and the capital return attached to it: On May 29, 2026 IFF agreed to sell its Food Ingredients business to funds advised by CVC Capital Partners at an enterprise value of about $4.3 billion, retaining a ~10% minority stake and expecting ~$3.8 billion of net cash proceeds. The bear case rests on the CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked. Analysts covering it publish targets from $76.00 to $110.00 against a $79.99 share price on November 16, 2026, so even the professionals disagree by 35% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
IFF key stats
At $79.99 on November 16, 2026, International Flavors & Fragrances Inc. (IFF) has a market cap of $20.0B, a P/E of 228.5 on trailing earnings (20.7 on forward earnings) and a dividend yield of 2.00%.
- Market cap
- $20.0B
- P/E (trailing)
- 228.5
- P/E (forward)
- 20.7
- EPS (trailing 12 months)
- $0.35
- Price to book
- 1.5
- Dividend yield
- 2.00%
- Beta
- 0.88
Market cap, P/E and yield are measured at the $79.99 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with International Flavors & Fragrances Inc. (IFF)?
The last two weeks for International Flavors & Fragrances Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- IFF closed at $79.99 on November 16, 2026, down 5.3% over the past five trading days (from $84.43).
- On November 3, 2026, International Flavors & Fragrances Inc. filed an 8-K with the SEC reporting a change in its directors or officers and an amendment to its charter or bylaws (Item 5.02, Item 5.03). Read the 8-K on sec.gov
- On November 3, 2026, International Flavors & Fragrances Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 3, 2026, International Flavors & Fragrances Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 6, 2026, Barclays lowered its target to $103.00 from $105.00 (Overweight).
- On November 6, 2026, UBS raised its target to $95.00 from $91.00 (Neutral).
- On November 5, 2026, JP Morgan raised its target to $95.00 from $92.00 (Overweight).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
International Flavors & Fragrances makes the taste, scent and functional ingredients that go into other companies' products: flavor systems for beverages, snacks and dairy, fine and consumer fragrances, enzymes, cultures, probiotics and soy proteins. The company traces to 1833 and reached its current scale through the 2018 Frutarom acquisition and the February 2021 Reverse Morris Trust merger with DuPont's Nutrition & Biosciences division, a roughly $26 billion combination that made IFF one of the four global ingredient houses alongside Givaudan, dsm-firmenich and Symrise. As of the second quarter of 2026 it reports three continuing segments, Taste (~$688 million of quarterly sales), Health & Biosciences (~$601 million) and Scent (~$665 million), after moving the Food Ingredients and Soy Crush businesses into discontinued operations. The investment picture is a portfolio being cut down deliberately. The DuPont merger left IFF with well over $10 billion of debt and leverage above 4x, and management has worked it down through a run of disposals: Microbial Control to Lanxess, Savory Solutions to Kerry, Cosmetic Ingredients to Clariant for ~$810 million, Pharma Solutions to Roquette at an enterprise value of up to ~$2.85 billion in May 2025, and the German nitrocellulose business for ~$161 million. Net debt stood at ~$5.2 billion at June 30, 2026 and leverage at ~2.5x credit adjusted EBITDA, comfortably inside the 3.75x covenant. The Food Ingredients sale to CVC, expected to close by the end of the second quarter of 2027, is meant to fund more than $1 billion of further debt reduction and a $2.5 billion buyback, which leaves the question of whether the smaller, higher-margin remainder can grow enough to justify what the market already pays for it. The market has leaned toward yes. IFF closed at ~$90.43 on October 16, 2026, up ~33% year to date and ~45% over a year, near a 52 week high of ~$91.88 and roughly ~$23 billion of market value. Analysts have been lifting targets into the third quarter report on November 3, 2026, with Barclays moving to $105 from $96 and Argus to $95 from $85; consensus for the quarter is ~$0.81 of EPS on ~$1.91 billion of continuing-operations revenue. On the product side, IFF launched AQUASCENT, a water-based, concentrate-only fragrance technology, on September 30, and Omni-Bos PHY, a feed additive for dairy producers, in September.
The bull case: what would have to be true for $110.00
The most optimistic published target on IFF is $110.00, +37.5% from the $79.99 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. The Food Ingredients sale and the capital return attached to it
On May 29, 2026 IFF agreed to sell its Food Ingredients business to funds advised by CVC Capital Partners at an enterprise value of about $4.3 billion, retaining a ~10% minority stake and expecting ~$3.8 billion of net cash proceeds. Management has committed more than $1 billion of that to debt reduction, targeting 2.0x to 2.5x net debt to EBITDA, and the board authorized a $2.5 billion repurchase program including a $500 million accelerated buyback in the second half of 2026. The remaining $2.0 billion is contingent on closing, which is guided to the end of the second quarter of 2027.
2. Deleveraging from the DuPont merger is essentially complete
Net debt was ~$5.2 billion against ~$569 million of cash at June 30, 2026, and the credit-agreement leverage ratio was ~2.51x versus a 3.75x maximum. Interest expense in the second quarter fell to ~$46 million from ~$61 million a year earlier, and a 2025 debt tender produced a ~$488 million gain on extinguishment. A $1.0 billion delayed draw term loan signed in June 2026 refinances the 800 million euro notes maturing in September 2026 and must be prepaid in full from the Food Ingredients proceeds.
3. Volume-led growth in Scent and Health & Biosciences
Second quarter continuing-operations sales of ~$1.95 billion rose ~6% on a comparable currency-neutral basis, led by high-single-digit growth in Scent (~$665 million, helped by double-digit Fragrance Ingredients) and mid-single-digit growth in Taste and Health & Biosciences. Management attributes the gain to volume rather than price, which matters after several years in which reported growth leaned on pricing. Health & Biosciences carries the best segment margin at ~25.0% adjusted operating EBITDA. New launches in the third quarter, AQUASCENT in fragrance and Omni-Bos PHY in animal nutrition, extend that volume story into newer formats.
4. Margin mix once the low-margin segment leaves
Adjusted operating EBITDA margin was ~20.9% on continuing operations in the second quarter, against ~19.7% including the businesses being sold. Full-year 2026 guidance on the new basis calls for ~$7.4 billion to ~$7.6 billion of sales and ~$1.53 billion to ~$1.60 billion of adjusted operating EBITDA, implying currency-neutral EBITDA growth of 4% to 8%. Whether that margin holds depends on how quickly IFF removes the overhead that supported roughly $3.2 billion of departing revenue.
The bear case: what would have to be true for $76.00
The most pessimistic published target is $76.00, -5.0% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks International Flavors & Fragrances Inc. is worth if the risks below bite instead of the drivers above.
The CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked. Stranded costs are the near-term execution problem: roughly $3.2 billion of sales and ~$520 million of EBITDA leave the company, and the overhead that supported them has to be removed for the stated margin uplift to be real. GAAP earnings remain thin relative to the market value, with trailing continuing-operations net income of ~$277 million against a ~$23 billion capitalization (Yahoo Finance shows a ~$791 million trailing loss once discontinued operations are included), because ~$948 million of annual depreciation and amortization and a string of disposal charges sit between EBITDA and reported profit. After a ~45% one year rally the shares also carry less valuation cushion if the November 3 report disappoints, and Yahoo Finance records second quarter EPS of ~$0.82 against a ~$1.12 estimate, though the reclassification of Food Ingredients muddies that comparison. Goodwill of ~$8.1 billion and intangibles of ~$3.7 billion still make up a large share of a ~$14.0 billion equity base that already absorbed multi-billion-dollar impairments in 2022 and 2023, so further writedowns are possible if end markets soften. Antitrust exposure is also open: European Commission, UK CMA and Swiss inspections of fragrance pricing continue, and while IFF settled the U.S. civil class actions for roughly $43 million in provisions, an Israeli class action over a Frutarom-era bonus was certified in September 2025 with a rehearing motion still pending.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding IFF already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on IFF
17 analysts cover IFF, with an average target of $98.24 (+22.8% against $79.99) and a split of 14 buy, 5 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the IFF forecast and price target page.
How is IFF valued?
Market cap, P/E and dividend yield at today's price are in the IFF key stats above. The business figures below come from International Flavors & Fragrances Inc.'s reported results as of October 2026 and change when it next reports.
- Revenue (TTM, all businesses): ~$10.8B; Q2 2026 ~$2.78B including discontinued operations
- FY 2026 sales guidance (continuing operations): ~$7.4B to ~$7.6B; consensus ~$7.59B
- Q2 2026 adjusted operating EBITDA margin: ~20.9%
- Net debt and leverage: ~$5.2B, ~2.5x credit adjusted EBITDA (June 30, 2026)
- Dividend: $1.60 annualized, ~1.8% yield
As of October 2026: The two revenue figures are not a contradiction: trailing revenue of ~$10.8 billion covers the whole company, while 2026 guidance of ~$7.4 billion to ~$7.6 billion covers only the three segments IFF is keeping, since Food Ingredients and the Soy Crush businesses moved to discontinued operations in the second quarter. Trailing GAAP EPS of ~$1.01 puts the shares near 90 times earnings, a number distorted by amortization and disposal charges, which is why the forward multiple of roughly 23 times on ~$3.96 of expected 2027 EPS is the one most analysts quote. Yahoo Finance puts enterprise value near 15 times trailing EBITDA, while Food Ingredients is being sold at roughly 8 times its own EBITDA; 17 analysts carry a mean target near ~$97.
How do you decide if IFF is a buy?
Whether IFF is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold IFF indirectly through an index or sector ETF before adding more.
What would change your mind on IFF
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: The Food Ingredients sale and the capital return attached to it stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: the CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the IFF stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about IFF against your real portfolio and see your actual exposure before deciding.
Your questions about International Flavors & Fragrances Inc.
Ask Walnut's AI anything about IFF and see how it fits what you own.
FAQ
Is IFF a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on The Food Ingredients sale and the capital return attached to it, with revenue (ttm, all businesses) at ~$10.8B; Q2 2026 ~$2.78B including discontinued operations. The bear case rests on the CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked. Analysts covering it are spread from $76.00 to $110.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell IFF?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $76.00, -5.0% from the $79.99 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for IFF?
+
The Food Ingredients sale and the capital return attached to it. On May 29, 2026 IFF agreed to sell its Food Ingredients business to funds advised by CVC Capital Partners at an enterprise value of about $4.3 billion, retaining a ~10% minority stake and expecting ~$3.8 billion of net cash proceeds. The most optimistic analyst target on IFF is $110.00, +37.5% from the $79.99 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for IFF?
+
The CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked. Stranded costs are the near-term execution problem: roughly $3.2 billion of sales and ~$520 million of EBITDA leave the company, and the overhead that supported them has to be removed for the stated margin uplift to be real. GAAP earnings remain thin relative to the market value, with trailing continuing-operations net income of ~$277 million against a ~$23 billion capitalization (Yahoo Finance shows a ~$791 million trailing loss once discontinued operations are included), because ~$948 million of annual depreciation and amortization and a string of disposal charges sit between EBITDA and reported profit. After a ~45% one year rally the shares also carry less valuation cushion if the November 3 report disappoints, and Yahoo Finance records second quarter EPS of ~$0.82 against a ~$1.12 estimate, though the reclassification of Food Ingredients muddies that comparison. Goodwill of ~$8.1 billion and intangibles of ~$3.7 billion still make up a large share of a ~$14.0 billion equity base that already absorbed multi-billion-dollar impairments in 2022 and 2023, so further writedowns are possible if end markets soften. Antitrust exposure is also open: European Commission, UK CMA and Swiss inspections of fragrance pricing continue, and while IFF settled the U.S. civil class actions for roughly $43 million in provisions, an Israeli class action over a Frutarom-era bonus was certified in September 2025 with a rehearing motion still pending. The most pessimistic published target is $76.00, -5.0% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does International Flavors & Fragrances Inc. do?
+
A global supplier of flavors, fragrances, enzymes and cultures to food, beverage, home care and personal care manufacturers.
What would have to change for IFF to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The Food Ingredients sale and the capital return attached to it) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does International Flavors & Fragrances actually make?
+
IFF supplies taste, scent and functional ingredients to other manufacturers rather than selling to consumers directly. That covers flavor systems for beverages, dairy, snacks and savory foods, fine and consumer fragrances, fragrance ingredients, and a biosciences portfolio of enzymes, cultures, probiotics and soy proteins. Its products end up in soft drinks, perfumes, detergents, supplements and animal nutrition under other companies' brands.
Why is IFF selling its Food Ingredients business?
+
Food Ingredients was the lowest-margin part of the portfolio, and selling it lifts group adjusted operating EBITDA margin from about 19.7% to about 20.9% on the second quarter numbers. The May 2026 agreement with CVC Capital Partners values the unit at roughly $4.3 billion and should yield about $3.8 billion of net cash, with IFF keeping a ~10% stake. Management intends to use the money for more than $1 billion of debt reduction and a $2.5 billion buyback.
Is IFF still working off debt from the DuPont merger?
+
Most of it is done. The 2021 Reverse Morris Trust merger with DuPont's Nutrition & Biosciences division pushed leverage above 4x, and a series of disposals including Pharma Solutions to Roquette and Cosmetic Ingredients to Clariant brought net debt to ~$5.2 billion and leverage to ~2.51x by June 30, 2026. That sits well inside the 3.75x credit agreement covenant, and the Food Ingredients proceeds are earmarked to take it lower.
Walnut is informational, not investment advice, and gives no verdict on IFF. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.